MedTrace Logo

Rosiglitazone Versus Placebo in Chronic Stable Angina

NCT00225355 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-02-19

No results posted yet for this study

Summary

We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not have overt diabetes. The drug will be given for 3 months and the subjects will be have their angina tested, by way of exercise testing, angina quality of life questionnaire and 24-hour ECG monitoring before and after using the drug.

Conditions

  • Angina Pectoris
  • Metabolic Syndrome X

Interventions

DRUG

Rosiglitazone

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Naveed Sattar, MBChB PhD · University of Glasgow

  • Stuart M Cobbe, MBChB MD · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2006-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225355 on ClinicalTrials.gov